This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (8)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Medical Practice  • Law and Medicine  • Patient Safety/ Medical Error  • Drug Therapy  • Adverse Effects  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Aaron S. Kesselheim, MD, JD; Jerry Avorn, MD

JAMA. 2007;297:308-311.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In the past decade, several widely used prescription medications have been observed to cause life-threatening adverse effects, and some have been removed from the market. When an approved medication is found to be unsafe, the courts are sometimes called on to determine fault and allocate remedies for injured parties. But in modern prescription drug cases, litigation has taken on additional significance. There are often important gaps in the ascertainment and reporting of adverse effects associated with prescription drugs, and the balance of information presented to physicians about the risks and benefits of medications may understate the former and inflate the latter.¹ However, once it approves a drug, the US Food and Drug Administration (FDA) has limited authority to mandate further collection of data to better define adverse effects or to ensure compliance with suggested alterations in marketing practices.² In this environment, litigation . . . [Full Text of this Article]

Sources of Knowledge About Drug Safety

Author Affiliations: Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The New Food and Drug Administration Drug Package Insert: Implications for Patient Safety and Clinical Care
Watson and Barash
Anesth. Analg. 2009;108:211-218.
ABSTRACT | FULL TEXT  

Prescription Drugs, Products Liability, and Preemption of Tort Litigation
DeAngelis and Fontanarosa
JAMA 2008;300:1939-1941.
FULL TEXT  

Clinical trials in stem cell transplantation: guidelines for scientific and ethical review
Lo et al.
Clin Trials 2008;5:517-522.
ABSTRACT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies--Reply
Ross et al.
JAMA 2008;300:904-905.
FULL TEXT  

The ADVANTAGE Seeding Trial: A Review of Internal Documents
Hill et al.
ANN INTERN MED 2008;149:251-258.
ABSTRACT | FULL TEXT  

The Deregulatory Effects of Preempting Tort Litigation: FDA Regulation of Medical Devices
Gostin
JAMA 2008;299:2313-2316.
FULL TEXT  

Pharmaceutical Promotion to Physicians and First Amendment Rights
Kesselheim and Avorn
NEJM 2008;358:1727-1732.
FULL TEXT  

Guest Authorship and Ghostwriting in Publications Related to Rofecoxib: A Case Study of Industry Documents From Rofecoxib Litigation
Ross et al.
JAMA 2008;299:1800-1812.
ABSTRACT | FULL TEXT